Cargando…

Unifying heterogeneous expression data to predict targets for CAR-T cell therapy

Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression and is tumor specific. This strategy has been s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schreiner, Patrick, Velasquez, Mireya Paulina, Gottschalk, Stephen, Zhang, Jinghui, Fan, Yiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632331/ https://www.ncbi.nlm.nih.gov/pubmed/34858726 http://dx.doi.org/10.1080/2162402X.2021.2000109

Ejemplares similares

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
por: Epperly, Rebecca, et al.
Publicado: (2020)

MyD88/CD40 signaling retains CAR T cells in a less differentiated state
por: Prinzing, Brooke, et al.
Publicado: (2020)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
por: Kailayangiri, Sareetha, et al.
Publicado: (2020)

OPAL data acquisition: VME as the unifying element in a heterogeneous system
por: Hatzifotiadou, D
Publicado: (1988)

Unifying models of glioblastoma’s intratumoral heterogeneity
por: Lam, K H Brian, et al.
Publicado: (2020)

CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
por: Bębnowska, Dominika, et al.
Publicado: (2020)

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

WLCG Transfers Dashboard: a Unified Monitoring Tool for Heterogeneous Data Transfers
por: Andreeva, J, et al.
Publicado: (2014)

Target selection for CAR-T therapy
por: Wei, Jianshu, et al.
Publicado: (2019)

Revolutionizing car body manufacturing using a unified steel metallurgy concept
por: Lu, Qi, et al.
Publicado: (2021)

CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
por: Hebbar, Nikhil, et al.
Publicado: (2022)

Data-driven analysis of a mechanistic model of CAR T cell signaling predicts effects of cell-to-cell heterogeneity
por: Cess, Colin G., et al.
Publicado: (2019)

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC
por: Szoor, Arpad, et al.
Publicado: (2017)

Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
por: Bell, Matthew, et al.
Publicado: (2021)

Unified Method for Target and Non-Target Monitoring of Pesticide Residues in Fruits and Fruit Juices by Gas Chromatography-High Resolution Mass Spectrometry
por: Granados-Povedano, Mireya, et al.
Publicado: (2023)

MyD88/CD40-based inducible co-stimulation to improve CAR T cell therapy
por: Mata, Melinda, et al.
Publicado: (2015)

The expansion of targetable biomarkers for CAR T cell therapy
por: Townsend, Michelle H., et al.
Publicado: (2018)

Podoplanin as an Attractive Target of CAR T Cell Therapy
por: Waseda, Masazumi, et al.
Publicado: (2020)

Gene Targets of CAR-T Cell Therapy for Glioblastoma
por: Wang, Chaoqun, et al.
Publicado: (2023)

Performance of CUDA Unified Memory in CMS Heterogeneous Pixel Reconstruction
por: Kwok, Ka Hei Martin
Publicado: (2021)

Performance of CUDA Unified Memory in CMS Heterogeneous Pixel Reconstruction
por: Kortelainen, Matti J, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
por: DeRenzo, Christopher, et al.
Publicado: (2019)

CAR‐T therapy: Prospects in targeting cancer stem cells
por: Cui, Xiaoyue, et al.
Publicado: (2021)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Costimulation to enhance the antitumor activity of CD19 eng T cells
por: Velasquez, Mireya, et al.
Publicado: (2015)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

318 Building A Better CAR: Improving CAR-T Trafficking in Cancer Therapy
por: Hong, Yeonsun, et al.
Publicado: (2022)

Targeting in Language: Unifying Deixis and Anaphora
por: Talmy, Leonard
Publicado: (2020)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies
por: Velasquez, Mireya Paulina, et al.
Publicado: (2016)

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity
por: Correia, Margareta P., et al.
Publicado: (2021)

Building a Unified Data Infrastructure
por: LaPlante, Alice
Publicado: (2020)

DataSpread: Unifying Databases and Spreadsheets
por: Bendre, Mangesh, et al.
Publicado: (2015)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_au9vf4m5jbclvbc90msdnvm8bc